Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 3/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | RRM1 | P23921 | 1/20 | 0.34 |
| ▸ | RRM2 | P31350 | 1/20 | 0.34 |
| ▸ | RRM2B | Q7LG56 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 3/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | EED | O75530 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24966013 | 0.91 | CASP3 (0.39) | CASP3PTPN1RRM1RRM2RRM2B | |
| SCHEMBL24966009 | 0.91 | CASP3 (0.39) | CASP3PTPN1RRM1RRM2RRM2B | |
| SCHEMBL22605955 | 0.90 | FPR2 (0.39) | CASP3RRM1RRM2RRM2BFPR2 | |
| SCHEMBL22605956 | 0.90 | FPR2 (0.39) | CASP3RRM1RRM2RRM2BFPR2 | |
| SCHEMBL29709595 | 0.89 | CASP3 (0.41) | CASP3PTPN1RRM1RRM2RRM2B | |
| SCHEMBL24965940 | 0.88 | CASP3 (0.38) | CASP3BACE1 | |
| SCHEMBL24965939 | 0.88 | CASP3 (0.38) | CASP3BACE1 | |
| SCHEMBL24964996 | 0.84 | PTPN1 (0.32) | PTPN1REN | |
| SCHEMBL30278725 | 0.82 | OPRK1 (0.43) | CASP3PTPN1FPR2 | |
| SCHEMBL30278723 | 0.82 | OPRK1 (0.43) | CASP3PTPN1FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230026641-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026641-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID | DNPEP, VIP, NPEPPS | CASP3 1864/4885PTPN1 2866/4885RRM1 3109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.